Karina Mayumi Sakita

Karina Mayumi Sakita

Auto-generated profile, based on publicly available information

Karina Mayumi Sakita

Medical Mycology Laboratory, Department of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, Brazil

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
PCPollyanna C.V. Conrado
Pollyanna C.V. Conrado
KSKarina M. Sakita
Karina M. Sakita
GAGlaucia S. Arita
Glaucia S. Arita
CGCamila B. Galinari
Camila B. Galinari
RGRenato S. Gonçalves
Renato S. Gonçalves
Erika Seki Kioshima CoticaErika Seki Kioshima Cotica
Erika Seki Kioshima Cotica

7 March 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
DFDaniella Renata Faria
Daniella Renata Faria
RMRaquel Cabral Melo
Raquel Cabral Melo
GAGlaucia Sayuri Arita
Glaucia Sayuri Arita
KSKarina Mayumi Sakita
Karina Mayumi Sakita
FRFranciele Abigail Vilugron Rodrigues-Vendramini
Franciele Abigail Vilugron Rodrigues-Vendramini
Erika Seki Kioshima CoticaErika Seki Kioshima Cotica
Erika Seki Kioshima Cotica
Candida albicans is the most common species isolated from nosocomial bloodstream infections. Due to limited therapeutic arsenal and increase of drug resistance, there is an urgent need for new antifungals. Therefore, the antifungal activity against C. albicans and in vivo toxicity of a 1,3,4-oxadiazole compound (LMM6) was evaluated. This compound was selected by in silico approach based on chemical similarity. LMM6 was highly effective against several clinical C. albicans isolates, with minimum inhibitory concentration values ranging from 8 to 32 µg/mL. This compound also showed synergic effect with amphotericin B and caspofungin. In addition, quantitative assay showed that LMM6 exhibited a fungicidal profile and a promising anti-biofilm activity, pointing to its therapeutic potential. The evaluation of acute toxicity indicated that LMM6 is safe for preclinical trials. No mortality and no alterations in the investigated parameters were observed. In addition, no substantial alteration was found in Hippocratic screening, biochemical or hematological analyzes. LMM6 (5 mg/kg twice a day) was able to reduce both spleen and kidneys fungal burden and further, promoted the suppresses of inflammatory cytokines, resulting in infection control. These preclinical findings support future application of LMM6 as potential antifungal in the treatment of invasive candidiasis.

1 January 2017 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
PRPâmela Guimarães Reis
Pâmela Guimarães Reis
CAChristiane Ayo
Christiane Ayo
LMLuiz Carlos De Mattos
Luiz Carlos De Mattos
Cinara Cássia BrandãoCinara Cássia Brandão
Cinara Cássia Brandão
KSKarina Mayumi Sakita
Karina Mayumi Sakita
Jeane Eliete Laguila VisentainerJeane Eliete Laguila Visentainer
Jeane Eliete Laguila Visentainer
The aim of this study was to investigate possible associations between genetic polymorphisms ofIL17AG197A (rs2275913) andIL17FT7488C (rs763780) with Chagas Disease (CD) and/or the severity of left ventricular systolic dysfunction (LVSD) in patients with chronic Chagas cardiomyopathy (CCC). The study with 260 patients and 150 controls was conducted in the South and Southeast regions of Brazil. The genotyping was performed by PCR-RFLP. The A allele and A/A genotype ofIL17Awere significantly increased in patients and their subgroups (patients with CCC; patients with CCC and LVSD; and patients with CCC and severe LVSD) when compared to the control group. The analysis according to the gender showed that the A/A genotype ofIL17Awas more frequent in female with LVSD and mild to moderate LVSD and also in male patients with LVSD. The frequency ofIL17FT/C genotype was higher in male patients with CCC and severe LVSD and in female with mild to moderate LVSD. The results suggest the possible involvement of the polymorphisms ofIL17AandIL17Fin the susceptibility to chronic Chagas disease and in development and progression of cardiomyopathy.

17 February 2021 in Future Microbiology
Verified
Journal Article
Closed access
PBPatricia Bonfim
Patricia Bonfim
FTFlávia K Tobaldini-Valério
Flávia K Tobaldini-Valério
ICIsis Rg Capoci
Isis Rg Capoci
DFDaniella R Faria
Daniella R Faria
KSKarina M Sakita
Karina M Sakita
TSTerezinha Svidzinski
Terezinha Svidzinski
Aim: To study the behavior of Candida albicans from women with vulvovaginal candidiasis (VVC), recurrent VVC (RVVC) and asymptomatic (AS), regarding adhesion on HeLa cells and their ability to expr...

1 July 2020 in Future Microbiology
Verified
Journal Article
Closed access
VMValéria Mosca
Valéria Mosca
GAGlaucia S Arita
Glaucia S Arita
LVLenisa V Vilegas
Lenisa V Vilegas
DFDaniella R Faria
Daniella R Faria
KSKarina M Sakita
Karina M Sakita
TSTerezinha Svidzinski
Terezinha Svidzinski
Aim: To compare the pathogenesis of vulvovaginal candidiasis by three Candida species in diabetic mice. Materials & methods: Estrogenized and diabetic mice were challenged with C. albicans, C. trop...

1 May 2023 in Journal of Molecular Structure
Verified
Journal Article
Closed access
KSKarina Mayumi Sakita
Karina Mayumi Sakita
FRFranciele Abigail Vilugron Rodrigues-Vendramini
Franciele Abigail Vilugron Rodrigues-Vendramini
TSTerezinha Svidzinski
Terezinha Svidzinski
MFMaria Sueli Felipe
Maria Sueli Felipe
BMBernard Maigret
Bernard Maigret
Erika Seki Kioshima CoticaErika Seki Kioshima Cotica
Erika Seki Kioshima Cotica